myriad_S_stacked.png
Myriad Genetics CEO Paul J. Diaz to Present at Goldman Sachs 2021 Virtual Global Healthcare Conference
June 04, 2021 07:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, June 04, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the company’s...
myriad_S_stacked.png
Myriad Genetics Completes the Sale of Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences
June 01, 2021 07:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) -- On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned...
myriad_S_stacked.png
Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions
May 24, 2021 07:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, May 24, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced it has signed a definitive agreement to...
myriad_S_stacked.png
Myriad Genetics Appoints Melissa Gonzales to Lead Women’s Health Business
May 20, 2021 07:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, May 20, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Melissa Gonzales has been named...
myriad_S_stacked.png
Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries
May 19, 2021 17:55 ET | Myriad Genetics, Inc.
SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will present results from a study...
myriad_S_stacked.png
Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference
May 05, 2021 16:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, May 05, 2021 (GLOBE NEWSWIRE) -- Paul J. Diaz, president and CEO of Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will discuss the...
myriad logo.jpg
Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives
May 03, 2021 16:05 ET | Myriad Genetics, Inc.
Highlights: Revenue of $173.1 million increases 12% sequentiallyGAAP earnings per share of ($0.52), adjusted EPS of ($0.06) improves $0.06 sequentiallyTotal test volumes increase 5% sequentially...
myriad logo.jpg
Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune’s Vectra Testing Business to Labcorp
May 03, 2021 07:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that it has entered into a definitive agreement...
myriad logo.jpg
Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day
May 03, 2021 07:00 ET | Myriad Genetics, Inc.
SALT LAKE CITY, May 03, 2021 (GLOBE NEWSWIRE) -- At its 2021 Investor Day, Myriad Genetics, Inc. (NASDAQ: MYGN), today will provide a strategic business update, including an overview of initiatives...
myriad logo.jpg
Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment
April 28, 2021 07:05 ET | Myriad Genetics, Inc.
SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) -- In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others...